Advanced DNA sequencing test used to match rare cancers

Bookmark and Share
Published: 1 Jun 2015
Views: 2063
Dr James Doroshow, Dr Keith Flaherty and Dr Barbara Conley

Dr Doroshow (National Cancer Institute, Bethesda, USA), Dr Flaherty (Massachusetts General Hospital, Boston, USA) and Dr Conley (Division of Cancer Treatment & Diagnosis, NCI , USA) present, at a press conference at ASCO 2015, about the trial: NCI-Molecular Analysis for Therapy Choice (NCI-MATCH)

A clinical trial that will analyse patients’ tumours to determine whether they contain genetic abnormalities for which a targeted drug exists (that is, “actionable mutations”) and assign treatment based on the abnormality.